A Shortage Becomes a Strategy
Wegovy arrived on the market with extraordinary momentum – Novo Nordisk could barely manufacture it fast enough to meet demand. For months, patients and prescribers were caught in a cycle of backorders, substitutions, and rationing, with some pharmacies limiting fills to existing customers only. What began as a production logistics problem gradually became a commercial liability, creating visible frustration among patients who had started treatment and suddenly couldn’t get their next dose.
That frustration is now Eli Lilly’s most valuable asset. Mounjaro and Zepbound, Lilly’s GLP-1 offerings, have been steadily filling the gap left by Wegovy’s supply inconsistencies. The opening wasn’t manufactured through marketing spend or price cuts – it arrived by default, and Lilly has been quietly capitalizing on it ever since.
How the Supply Gap Developed
Novo Nordisk’s capacity constraints weren’t a secret. The company publicly acknowledged manufacturing challenges as demand for semaglutide outpaced its fill-and-finish infrastructure. Scaling a biologic drug isn’t like ramping up a consumer product line – it requires specialized sterile manufacturing facilities, long lead times for equipment, and regulatory clearances at every stage. Even with aggressive capital investment, that kind of expansion takes years, not quarters.
The real damage came from inconsistency. Patients who experienced supply disruptions mid-treatment faced a specific clinical problem: stopping and restarting GLP-1 medications isn’t seamless from a dosing or appetite-regulation standpoint. Some patients, left without reliable access, made a practical decision to switch. That switching behavior is exactly where Lilly found its opening – not by poaching Wegovy users through advertising, but by being available when Novo Nordisk wasn’t.
Compounding pharmacies also flooded the market during the shortage, producing semaglutide copies that the FDA permitted under shortage conditions. This muddied Novo Nordisk’s brand position and introduced a price-competitive alternative that attracted cost-sensitive patients who might otherwise have stayed loyal. Lilly faced a smaller version of the same compounding problem with tirzepatide, but its supply held more consistently, which limited how much ground the compounders could take.
Lilly’s Position Right Now
Zepbound, Lilly’s FDA-approved version of tirzepatide for weight loss, launched in late 2023 and has seen accelerating prescriptions through 2024. The drug’s clinical profile – showing slightly higher average weight loss in trials compared to semaglutide – gave prescribers a medically defensible reason to try it. When Wegovy shortages gave patients a logistical reason, the combination proved effective at building Lilly’s patient base.
Lilly has also moved aggressively on direct-to-consumer access. Its LillyDirect platform connects patients with telehealth providers and pharmacy partners, reducing friction in the prescribing and fulfillment process. That infrastructure investment now looks prescient – not because it anticipated Novo Nordisk’s supply struggles specifically, but because it built a path to patients that doesn’t depend on traditional pharmacy availability, which is exactly where the supply chain cracked for Wegovy.
What This Means for the GLP-1 Market
The weight-loss drug market is still young enough that first impressions carry unusual weight. Patients who switched to Zepbound during the Wegovy shortage and had a positive experience aren’t automatically going back. Brand loyalty in pharmaceuticals is partly inertia – once a patient is stable on a medication and their insurer covers it, switching again requires active motivation. Novo Nordisk faces the structural challenge of winning back patients who didn’t choose to leave but simply couldn’t get their prescription filled.
There’s also a prescriber-level dynamic at play. Physicians who recommended Wegovy to patients and then fielded calls about backorders and unavailability are now more willing to lead with Zepbound for new patients. That’s a reputational cost that doesn’t show up directly in Novo Nordisk’s quarterly filings but compounds over time in prescription data. A doctor who gets burned once by recommending a drug that patients can’t fill will quietly adjust their default recommendation.
Novo Nordisk hasn’t stood still. The company has announced significant manufacturing investments, including a multi-billion dollar facility expansion in the United States. Ozempic, the diabetes-approved version of semaglutide, has seen more consistent supply than Wegovy, and the company has pushed regulators and insurers on access issues. But catching up in a market that’s moving this fast means Lilly has time to harden its position before Novo Nordisk’s production capacity fully stabilizes.
The longer arc here is genuinely uncertain. Novo Nordisk is developing oral semaglutide formulations that could change how patients access the drug entirely, bypassing the injectable supply chain that caused so much of the original friction. Lilly, for its part, has its own pipeline candidates behind tirzepatide. But right now, in the middle of 2025, Lilly holds the operational advantage – and in a market where patients are actively seeking these drugs, being available is often more persuasive than being superior.
Frequently Asked Questions
Why has Wegovy faced supply shortages?
Scaling biologic drug manufacturing requires specialized facilities and regulatory approvals, making rapid production increases extremely difficult even with heavy investment.
How is Eli Lilly benefiting from Wegovy’s shortage?
Lilly’s Zepbound and Mounjaro have attracted patients who couldn’t access Wegovy, and its LillyDirect platform makes fulfillment easier, helping it build a loyal patient base.
